Robert Spiegel - Sucampo Pharmaceuticals Director
Director
Dr. Robert J. Spiegel, M.D., FACP is an Independent Director of Company. Dr. Spiegel was Chief Medical Officer of ScheringPlough and was involved in the successful filing of over 30 New Drug Applications. He also served on the executive committees overseeing research projects and drug licensing activities. Dr. Spiegel joined ScheringPlough in 1983 as Director, Clinical Research, progressing through clinical operations as Vice President of Clinical Research, Senior Vice President of Worldwide Clinical Research and then becoming Chief Medical Officer in 1998. He received his undergraduate degree, cum laude, from Yale University and his medical degree from the University of Pennsylvania. He is currently an Associate Professor at Weill Cornell Medical Center and serves on the board of directors and scientific advisory committees of a number of companies. Dr. Spiegel also currently serves as Chief Medical Officer at PTC Therapeutics. since 2015.
| Age | 67 |
| Tenure | 9 years |
| Phone | 301 961-3400 |
| Web | www.sucampo.com |
Robert Spiegel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Spiegel against Sucampo Pharmaceuticals stock is an integral part of due diligence when investing in Sucampo Pharmaceuticals. Robert Spiegel insider activity provides valuable insight into whether Sucampo Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Sucampo Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sucampo Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Spiegel over a week ago Acquisition by Robert Spiegel of 125000 shares of Geron at 3.27 subject to Rule 16b-3 | ||
Robert Spiegel over three months ago Acquisition by Robert Spiegel of 3406 shares of Geron subject to Rule 16b-3 | ||
Robert Spiegel over six months ago Acquisition by Robert Spiegel of 3390 shares of Geron subject to Rule 16b-3 | ||
Robert Spiegel over six months ago Acquisition by Robert Spiegel of 22 shares of Geron subject to Rule 16b-3 |
Sucampo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0296 % which means that it generated a profit of $0.0296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 14.16 %, meaning that it created $14.16 on every $100 dollars invested by stockholders. Sucampo Pharmaceuticals' management efficiency ratios could be used to measure how well Sucampo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 293.54 M in liabilities with Debt to Equity (D/E) ratio of 740.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sucampo Pharmaceuticals has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sucampo Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Sucampo Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sucampo Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sucampo to invest in growth at high rates of return. When we think about Sucampo Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James Kern | Tscan Therapeutics | 49 | |
| David Downes | Tscan Therapeutics | 76 | |
| Milton Matsumoto | Barings BDC | 70 | |
| Nancy Hawthorne | Tscan Therapeutics | 66 | |
| Wanna Khonsrichai | Pintec Technology Holdings | 56 | |
| Phirom Chamsai | Pintec Technology Holdings | 57 | |
| Deborah McAneny | Tscan Therapeutics | 58 | |
| Jill Olmstead | Barings BDC | 56 | |
| Keith Hughes | Tscan Therapeutics | 70 | |
| Carlos Guilherme | Barings BDC | 71 | |
| Jeffrey Joerres | Artisan Partners Asset | 61 | |
| Matthew Barger | Artisan Partners Asset | 62 | |
| Joao Alvarez | Barings BDC | 54 | |
| Stephanie DiMarco | Artisan Partners Asset | 62 | |
| Thomas Finke | Barings BDC | 53 | |
| Harin Upara | Pintec Technology Holdings | 42 | |
| Dorothy Clarke | Eterna Therapeutics | 58 | |
| Jane Nelson | Tscan Therapeutics | N/A | |
| Suraphan Puranakhup | Pintec Technology Holdings | N/A | |
| Admiral Giambastiani | Tscan Therapeutics | N/A | |
| Seth Brennan | Artisan Partners Asset | 47 | |
Management Performance
| Return On Equity | 14.16 | |||
| Return On Asset | 0.0296 |
Sucampo Pharmaceuticals Leadership Team
Elected by the shareholders, the Sucampo Pharmaceuticals' board of directors comprises two types of representatives: Sucampo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sucampo. The board's role is to monitor Sucampo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sucampo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sucampo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Munder, Independent Director | ||
| Peter Pfreundschuh, CFO, Principal Financial Officer | ||
| Matthew Donley, Executive VP of HR | ||
| Max Donley, Executive Vice President of Human Resources | ||
| Peter Kiener, Chief Scientific Officer | ||
| Matthias Alder, Executive Vice President - Business Development & Licensing | ||
| Daniel Getman, Independent Chairman of the Board | ||
| Peter Greenleaf, Chairman and CEO | ||
| Silvia Taylor, Senior Vice President - Investor Relations, Public Relations and Corporate Communications | ||
| Peter Lichtlen, Chief Medical Officer | ||
| Stanley Miele, Sr. VP of Sales and Marketing and President of Sucampo Pharma Americas LLC | ||
| Andrew Smith, Principal Accounting Officer | ||
| Timothy Walbert, Director | ||
| John Johnson, Director | ||
| Paul Edick, Director | ||
| Alex Driggs, Acting General Counsel, Corporate Secretary | ||
| Karen Smith, Director | ||
| Robert Spiegel, Director | ||
| Maureen OConnell, Independent Director | ||
| Thomas Knapp, Executive Vice President Chief Legal Officer and Corporate Secretary |
Sucampo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sucampo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 14.16 | |||
| Return On Asset | 0.0296 | |||
| Profit Margin | 7.80 % | |||
| Operating Margin | 30.77 % | |||
| Current Valuation | 1.05 B | |||
| Shares Outstanding | 47.09 M | |||
| Shares Owned By Insiders | 35.13 % | |||
| Shares Owned By Institutions | 82.48 % | |||
| Number Of Shares Shorted | 4.59 M | |||
| Price To Earning | (2.77) X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Sucampo Stock
If you are still planning to invest in Sucampo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sucampo Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |